News United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
262.4 ^USD	+1.65%		+12.21%	+19.33%

May. 03	United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	MT
May. 02	UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	May. 03	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	May. 02	MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating	May. 02	MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	May. 01	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M	May. 01	MT
United Therapeutics: Q1 Earnings Snapshot	May. 01	AQ
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
United Therapeutics Corporation Reports First Quarter 2024 Financial Results	May. 01	BU
UNITED THERAPEUTICS ANNOUNCES WORLD'S FIRST SUCCESSFUL XENOTHYMOKIDNEY TRANSPLANT	Apr. 25	AQ
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant	Apr. 24	BU
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024	Apr. 24	BU
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	Apr. 23	MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	Apr. 23	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference	Apr. 16	BU
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News United Therapeutics Corporation

Equities

UTHR

US91307C1027

Summary

Filters